drugset / Trial / NCT04570683
Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas
Non-randomizedSequentialOpen-labelTreatment
Summary
The study aim is to assess the immunological and clinical response in basal cell carcinoma (BCC) treated with ablative fractionated laser (AFL) as monotherapy and compare with BCC treated with combination-therapy of AFL and the anti-PD1-drug nivolumab and with nivolumab as monotherapy.
Timeline
- Start
- 2020-01-27
- Primary completion
- 2021-09
- Completion
- 2021-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nivolumab | Monoclonal antibody | 10 mg/ml | Other |